<DOC>
	<DOCNO>NCT01241773</DOCNO>
	<brief_summary>The purpose study investigate effect steady-state concentration TMC435 steady-state pharmacokinetics efavirenz raltegravir , vice versa . Steady state term mean drug give long enough plasma concentration remain subsequent dose . TMC435 investigate treatment chronic hepatitis C virus ( HCV ) infection . Efavirenz raltegravir two antiretroviral drug treatment human deficiency virus ( HIV ) infection . Pharmacokinetics ( pk ) mean drug absorb bloodstream , distribute body eliminate body .</brief_summary>
	<brief_title>TMC435-TiDP16-C123 - A Study Healthy Volunteers Investigating Pharmacokinetic Interaction Between TMC435 Antiretroviral Agents Efavirenz Raltegravir</brief_title>
	<detailed_description>TMC435 investigate treatment chronic hepatitis C virus ( HCV ) infection , combination Peg-IFN ( pegylated interferon ) RBV ( ribavirin ) . About 30 % HIV infect patient co-infected HCV need treatment infection . The result study provide dose recommendation coadministration TMC435 efavirenz raltegravir HIV-HCV co-infected patient . This Phase I , open-label ( participant investigator know name medication give certain moment ) , randomize ( sequence treatment study medication assign chance ) , crossover trial 48 healthy volunteer investigate pharmacokinetic interaction TMC435 antiretroviral agent ( efavirenz raltegravir ) , steady state . The volunteer allocate one two panel . In Panel 1 , volunteer receive three treatment ( treatment A-B-C ) randomize order . Volunteers receive TMC435 150 mg q.d. , efavirenz 600 mg q.d . efavirenz 600 mg q.d . + TMC435 150 mg q.d. , respectively . All treatment administer 14 day . There washout period ( period study drug take view medication eliminate body start new treatment ) least 14 day last intake study medication one session first intake study medication subsequent session . In Panel 2 , volunteer receive three treatment ( treatment D-E-F ) randomize order . Volunteers receive TMC435 150 mg q.d. , raltegravir 400 mg b.i.d . raltegravir 400 mg b.i.d . + TMC435 150 mg q.d. , respectively . All treatment administer 7 day . There washout period least 7 day . Pharmacokinetic profile three compound determine blood sample take regular interval study . Safety tolerability assess study period follow-up . Blood urine sample , electrocardiogram ( ECG ) vital sign ( blood pressure heart rate ) take screening , medication intake Days 1 14 Day 15 session Panel 1 , medication intake Days 1 7 Day8 session Panel 2 , 6 hour post dose Day14 Day7 Panel 1 2 , respectively 2 follow visit 1 week 4-5 week last dose study medication last session . A physical examination perform screening , Day-1 ( = day first medication intake session panel ) Day15 Panel 1 , Day-1 Day8 Panel 2 2 follow visit . Each volunteer receive 3 treatment 14 7 day ( Panel 1 2 , respectively ) , minimum 14 7 day apart ( Panel 1 2 , respectively ) . Volunteers Panel 1 take oral TMC435 150 mg q.d. , oral efavirenz 600 mg q.d . combine . Volunteers Panel 2 take oral TMC435 150 mg q.d. , oral raltegravir 400 mg b.i.d . combine .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Nosmoker least 3 month Body Mass Index 18.0 30.0 kg/m2 Healthy base medical evaluation include medical history , physical examination , blood test electrocardiogram Infection Hepatitis A , B C Virus Infection Human Immunodeficiency Virus ( HIV ) History , current medical condition could impact safety participant study Having previously participate multipledose trial TMC435 Having previously participate 3 singledose trial TMC435 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>TMC435-TiDP16-C123</keyword>
	<keyword>TMC435-C123</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>